Therapeutic effect of Xialiqi Capsule on benign prostatic hyperplasia

Second Hospital of Tianjin Medical University0 个研究点开始时间: 待定最近更新: 2023年2月20日

适应症

试验速览

暂无简介。

•1. Patients with BPH who have symptoms of frequent urination and dysuria, diagnosed by digital rectal examination, B-ultrasound, and uroflowmetry.
•2. IPSS>=13 and/or QOL>=3 points.
•3. Prostate volume > 25ml.
•4. The maximum urine flow rate is less than 15ml/s.
•5. Residual urine volume <100ml.
•6. Aged > 50 years.
•7. The patients voluntarily participated and signed the informed consent.
•8. PSA<4ng/ml or PSA>4ng/ml, but exclude patients with prostate cancer.
•9. In line with the dialectical standard of TCM spleen-kidney qi deficiency and phlegm stasis syndrome.

•1. With other diseases that cause urination disorders, such as prostate cancer.
•2. The patient or his authorizer is unwilling to comply with the study protocol.
•3. Upper urinary tract hydrops, bladder stones, repeated hematuria, urinary tract infections caused by benign prostatic hyperplasia.
•4. Patients with benign prostatic hyperplasia who have failed invasive treatment and who have a history of pelvic surgery or injury.
•5. Patients with severe diabetes, hypertension, cardiovascular and cerebrovascular diseases.
•6. Patients with major organ dysfunction, such as liver and kidney insufficiency.
•7. Psychopaths.
•8. Those with allergies.

发起方